XFOR
X4 Pharmaceuticals, Inc.
There isn't enough reported data to score XFOR yet.
XFOR Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Under pressure | |
| Unavailable |
XFOR's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
XFOR PE Valuation
XFOR has no meaningful PE right now: it lost money over the past year.
XFOR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Growth | |
| -- | |
| Limited | |
| Low |
Analysts expect XFOR's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
XFOR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$10.12 | -$8.32 |
| Q2 2025 | -$14.83 | -549% |
| Q1 2025 | $2.14 | +$22.24 |
| Q4 2024 | -$5.70 | +$11.40 |
| Q3 2022 | -$83.10 | +$27.90 |
| Q2 2022 | -$98.10 | +$16.20 |
| Q1 2022 | -$102.30 | +$12.60 |
| Q4 2021 | -$119.70 | -$27.00 |
XFOR is still losing money, but far less than before: $10.12 per share over the past year, against $119.70 at its worst in late 2021.
XFOR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.8M | +79% |
| Q2 2026 | $2.4M | +38% |
| Q1 2026 | $2.5M | +178% |
| Q4 2025 | $2.2M | +53% |
| Q3 2025 | $1.6M | +180% |
| Q2 2025 | $1.7M | +210% |
XFOR's revenue has grown year over year for 10 quarters in a row: $3M last quarter, up 79% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -714% | +1043 points |
| Q2 2026 | -683% | +821 points |
| Q1 2026 | -812% | +237 points |
| Q4 2025 | -1077% | +1413 points |
| Q3 2025 | -1757% | +4404 points |
| Q2 2025 | -1504% | -14133 points |
| Q1 2025 | -1049% | N/A |
| Q4 2024 | -2491% | N/A |
XFOR's operating margin was −714% last quarter, up 1043 points from the same quarter a year ago.
XFOR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$20.2M | +$7.6M |
| Q2 2026 | -$20.8M | +$9.1M |
| Q1 2026 | -$19.6M | -$7.2M |
| Q4 2025 | -$15.5M | +$17.5M |
| Q3 2025 | -$27.8M | +$6.3M |
| Q2 2025 | -$29.9M | +$34.1M |
| Q1 2025 | -$12.4M | +$21.3M |
| Q4 2024 | -$33M | -$5.3M |
XFOR has burned cash in almost every quarter: −$76M over the past year, against −$103M the year before.
XFOR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +180K shares |
| 1 year | +1607% | +119M shares |
| 3 years | +2149% | +121M shares |
| 5 years | +18192% | +126M shares |
| Available history | +18865% | +126M shares |
XFOR has 127M diluted shares, up 1607% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2023 | $443,000 |
| Q4 2022 | — |
| Q4 2021 | — |
XFOR Net Leverage
XFOR's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
XFOR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.7 | Neutral |
| Stochastic | 34.5 | Neutral |
XFOR's weekly RSI is 44 (neutral) and its Stochastic is 35 (neutral).
XFOR PE vs Healthcare Sector
| Metric | XFOR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
XFOR has no meaningful PE right now: it lost money over the past year.
XFOR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.04 | 4.3% above |
| 20 week MA | $3.63 | 13% below |
| 50 week MA | $3.81 | 17% below |
| 100 week MA | $5.35 | 41% below |
| 200 week MA | $18.2 | 83% below |
XFOR has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 83% below its 200-week average.
XFOR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $325.8 | $210.3 | -35% |
| 2021 | $210.3 | $74.1 | -65% |
| 2022 | $74.1 | $25.8 | -65% |
| 2023 | $25.8 | $25.2 | -2.6% |
| 2024 | $25.2 | $24.1 | -4.1% |
| 2025 | $24.1 | $4.50 | -81% |
| 2026 YTD | $4.50 | $3.17 | -30% |
XFOR has finished every year since 2020 lower, and it's down 30% so far in 2026.